Clinical trials
Adenocarcinoma clinical trials
Below are recruiting adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 995 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05788029Enrolling by invitation
Laparoscopic vs open pancreatic surgery for periampullary cancer
This trial compares two ways of doing a major pancreas-and-duodenum operation: laparoscopic (small incisions) versus open surgery (larger incision). It aims to see which approach works better for nonpancreatic periampullary adenocarcinoma when the goal is cure.
Wuhan, HubeiAges 18–75 - NCT05403242RecruitingPhase 1/Phase 2
Study drug RC48-ADC plus S-1 for advanced HER2 stomach cancers
This Phase 1/2 study tests RC48-ADC (an antibody-drug treatment) together with S-1 (a chemotherapy medicine) in people with advanced stomach or esophagus/gastroesophageal junction cancer. It’s mainly for cancers with HER2 testing results of IHC 2+ and FISH-negative, and aims to find a safe dose and how well the treatment works as a first treatment option.
BeijingAges 18 years+ - NCT05430035RecruitingEarly Phase 1
HIPEC for high-risk gallbladder cancer after surgery
This early-phase study tests whether a treatment called HIPEC is safe and feasible in people with high-risk gallbladder adenocarcinoma after surgery. HIPEC delivers chemotherapy directly into the abdomen during the operation to lower the chance of cancer coming back.
Morgantown, West VirginiaAges 18 years+ - NCT05356520Recruiting
Which operation is best for Siewert type II stomach cancer
This trial compares different surgical approaches for removing Siewert type II cancer at the esophagus–stomach junction. It aims to find which operation works best for people who can have the tumor removed.
Xi'an, ShaanxiAges 18–75 - NCT05630989Recruiting
Registry for outcomes in KRAS G12R pancreatic cancer on MEK therapy
This study keeps a registry (a secure database) to track how people with advanced pancreatic cancer and a KRAS G12R mutation do after treatment with a MEK inhibitor–based combination. It helps doctors understand which outcomes matter most for this specific genetic type of cancer.
Milwaukee, WisconsinAges 18 years+ - NCT04998552Recruiting
CyberKnife radiation for certain pancreatic cancer patients after chemotherapy
This trial studies how safe CyberKnife is when used to treat some borderline resectable or locally advanced pancreatic cancers after chemotherapy. It may help patients by targeting the tumor with precise radiation, while researchers closely watch for side effects.
Pennington, New JerseyAges 18 years+ - NCT04682158RecruitingPhase 2
Propranolol added to standard chemoradiation for esophageal cancer
This trial studies whether adding propranolol (a common blood-pressure/heart medication) to standard chemotherapy and radiation can improve outcomes for people with esophageal adenocarcinoma. You would start propranolol around the time of treatment, with careful heart monitoring and study follow-up.
Buffalo, New YorkAges 18 years+ - NCT06821997RecruitingPhase 2
Chemotherapy Before Surgery for Borderline Resectable Pancreatic Cancer
This trial is testing a combination of three chemotherapy drugs (NALIRIFOX) given before surgery to shrink borderline resectable pancreatic cancer. The goal is to help make surgery more successful and improve outcomes.
Buffalo, New YorkAges 18 years+ - NCT06947291RecruitingPhase 2
Study of glumetinib plus nab-docetaxel for advanced stomach cancer
This trial tests a combination of two drugs, glumetinib and nab-docetaxel, in people with advanced stomach cancer or other solid tumors that have a specific change in the MET gene. The goal is to see if this combination is safe and works better than current treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06157671Enrolling by invitation
Testing a new method to find early pancreatic cancer in high-risk people
This study is testing a new imaging method called LINFU® to see if it can find pancreatic cancer early in people who are at higher risk but have no symptoms. If you are at elevated risk for pancreatic cancer and are already getting imaging tests, this study may help improve early detection.
New York, New YorkAges 18–90 - NCT07118527RecruitingPhase 3
New drug combo for untreated advanced stomach cancer
This trial tests a new combination of an anti-HER2 drug (SHR-A1811) plus chemotherapy and an immunotherapy (adebrelimab) for people with untreated advanced stomach cancer. It aims to see if this combination works better than standard treatment.
Shenyang, LiaoningAges 18–75 - NCT07178340RecruitingPhase 2
Perioperative therapy for HER2-negative stomach cancer
This trial tests a treatment given before and after surgery for a rare type of stomach cancer called hepatoid adenocarcinoma. It aims to improve outcomes for patients whose tumors are HER2-negative and have not spread too far.
BeijingAges 18–75 - NCT06377527Recruiting
Tracking mesonephric-like adenocarcinoma cases
This study is creating a registry to collect information from patients with a rare type of gynecologic cancer called mesonephric-like adenocarcinoma (MLA) and related types. By joining, you help doctors learn more about this cancer to improve future care.
Houston, TexasAges 18 years+ - NCT06341335RecruitingPhase 3
AK104 and AK109 plus paclitaxel for advanced stomach cancer
This trial tests a combination of two experimental immunotherapies (AK104 and AK109) with a standard chemo drug (paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has grown after initial treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer better than chemo alone.
BeijingAges 18–75 - NCT06841679RecruitingPhase 2/Phase 3
Testing utidelone plus chemo for untreated stomach cancer
This trial tests a new capsule (utidelone) combined with standard chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. It aims to see if this combination works better than current options.
Hialeah, FloridaAges 18 years+ - NCT06406426RecruitingPhase 2
New drug combo for advanced stomach cancer after first treatment fails
This trial tests a combination of three drugs—cadonilimab, fruquintinib, and albumin-bound paclitaxel—as a second treatment for advanced stomach cancer. It may be an option if your first treatment stopped working and you have not had certain types of prior therapy.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06816914RecruitingPhase 2
Perioperative chemo for resectable pancreatic cancer
This trial tests a combination of chemotherapy drugs (liposomal irinotecan with fluorouracil, leucovorin, and oxaliplatin) given before and after surgery for pancreatic cancer that can be fully removed. It aims to see if this approach improves outcomes for patients with stage I or II disease.
Kaohsiung CityAges 20–75 - NCT06229496RecruitingPhase 1
Study of GAS for newly diagnosed advanced pancreatic cancer
This trial tests an oral medication called GAS in people with pancreatic cancer that has spread to other parts of the body, who have not yet received any treatment for metastatic disease. The goal is to find the best dose and see how well it works.
Chiayi CityAges 18 years+ - NCT07622940RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Esophageal Cancer
This trial tests a new immunotherapy using specially engineered natural killer cells (a type of immune cell) designed to target two proteins found on esophageal cancer cells. It's for patients with advanced esophageal adenocarcinoma that has spread or returned after prior treatment.
Shenzhen, GuangdongAges 18–75 - NCT06278545RecruitingPhase 2
Chemotherapy for unremovable small bowel cancer
This trial tests two standard chemotherapy combinations (FOLFIRINOX and FOLFOX) in people with small bowel adenocarcinoma that cannot be removed by surgery or has spread. It aims to see which works better for people who haven't had chemotherapy before.
DijonAges 18 years+ - NCT06289374Recruiting
Long-term breath & blood study after stomach or esophagus cancer surgery
This study is for people who have had surgery for stomach or esophagus adenocarcinoma and are already part of a larger study called BIORESOURCE 1. It looks at certain substances in your breath and blood over time to learn more about recovery.
LondonAges 18–90 - NCT06766578RecruitingPhase 2
Low-dose radiation plus immunotherapy and chemo before gastric cancer surgery
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
Jinan, ShandongAges 18–75 - NCT06761846RecruitingPhase 2
Immunotherapy and chemo after stomach cancer surgery
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from coming back. You may qualify if you had D2 surgery and your tumor tested positive for PD-L1.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07353684RecruitingPhase 2
Adebrelimab plus apatinib with chemo for gastric cancer
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adenocarcinoma?
- Yes. Clin2 currently lists 995 recruiting adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.